REMARKS

Further consideration of this application is requested. Claims 8-11 remain active in the application. Of these, claim 10 has been allowed while claims 8, 9 and 10 are rejected over U.S. patent 3,919,316 to Molloy. Claim 8 is amended to exclude the compound of Molloy by adding a further "proviso" to claim 8, namely item (e).

Applicants submit that the claims of this application are now in condition for allowance and that claims 8, 9 and 11 should also be allowed with claim 10.

Favorable action is solicited.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version With Markings To Show Changes Made**."

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____

Arthur R. Crawford
Reg. No. 25,327

ARC:pfc
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

8. (Twice Amended) A 2-aminoteraline of the formula (I)



(I)

or a pharmacologically acceptable salt of the formula (II)



(II)

wherein:

R and R_1 are independently halogen, hydroxy, or C_1-C_4 alkoxy optionally substituted in position ω with a group selected from OH, NH_2 or NR_3R_4, wherein R_3 and R_4 are independently H, C_1-C_4 alkyl, unsubstituted or substituted in position ω with groups OH, NH_2, C_1-C_4 alkanoyl, C_1-C_4 alkyl, carbamoyl, carbamoyloxy, amino, or amino-substituted NR_3R_4, where R_3 and R_4 have the above meanings,

R_2 is hydrogen, halogen, hydroxy or methoxy,

with the proviso that the 2-aminotetraline excludes (a) $R=R_1=CH_3O$ or OH, $R_2=H$, (b) $R=F$, $R_1=CH_3O$ or OH, $R_2=H$, (c) R_1=-OCH_3, $R=CH_3$ and $R_2=H$ [or] (d) $R=R_1=R_2=CH_3O$ or (e) $R=R_1=Cl$ and $R_2=H$,

and X^- is the monovalent anion of a pharmacologically acceptable acid.